Proof you can see. In every dose.
A dissolving microneedle patch with a built-in colour-change indicator — mechanistically coupled to needle dissolution. The colour confirms the dose. No devices, no training.
You can't approve a dose you can't verify.
Microneedle patches promise needle-free, cold-chain-free delivery. But existing trials share one fatal gap: nobody can prove the dose actually went in. Regulators and pharma require evidence of successful delivery — and current patches can't provide it.
Dosing inconsistency
Delivery varies between applications, with no way to detect a partial or failed dose at the point of care.
No field-level verification
In clinics and remote settings alike, there's no signal that the medicine was delivered — only that a patch was applied.
A regulatory roadblock
Without dose-delivery evidence, approval pathways stall. Verification isn't a nice-to-have — it's a gate.
The patch shows its work.
VisiPatch is a dissolving microneedle patch whose colour change is mechanistically coupled to needle dissolution. As the needles dissolve and deliver, the patch changes colour — turning successful delivery into something anyone can see, with no reader, no device, and no training.
Visual confirmation, in real time
The colour confirms the dose at the moment of delivery — eliminating user error and building patient confidence.
Thermostable by design
No cold chain to maintain. The patch survives where refrigeration can't reach, cutting wastage and widening access.
Self-administered
No clinician, no sharps, no needle phobia. A patch a person can apply themselves — and verify themselves.
A verification layer for a market already moving.
Microneedle delivery is no longer speculative. Procurement is underway — and the platform that can prove delivery is positioned to lead it.
Built by the people who invented it.
Founded on patented research from Queen's University Belfast, advised by leaders in microneedle science, pharma development, and regulatory submission.
Huanhuan Li, PhD, RAEng Enterprise Fellow
Under NDA
Ryan Donnelly, Prof
Stephen Liggett, PhD
Target partners.
We're building relationships across the value chain — from molecule owners to the funders and manufacturers who bring delivery to scale.
Let's talk about delivery you can verify.
Whether you're evaluating a partnership, exploring funding, or want to see the data — we'd like to hear from you.
Message sent
Thanks — we've received your note and will be in touch shortly.